一种GSH消耗型纳米疫苗及其应用
By preparing the GSH-consuming nanovaccine HA@PC-OVA, and utilizing cinnamaldehyde-grafted polyethyleneimine to bind with ovalbumin and hyaluronic acid, the problem of low delivery efficiency of traditional tumor vaccines was solved. This activated dendritic cell maturation, enhanced anti-tumor immune response, and achieved highly efficient tumor treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHINA PHARM UNIV
- Filing Date
- 2023-12-14
- Publication Date
- 2026-07-17
AI Technical Summary
Traditional tumor vaccines have limitations in antigen delivery and presentation efficiency, which restricts their application in tumor immunotherapy. Furthermore, high levels of GSH in the tumor microenvironment lead to immunosuppression, affecting treatment efficacy.
Using cinnamaldehyde-grafted polyethyleneimine (PEI-Cin) as a carrier material, it is combined with ovalbumin (OVA) and hyaluronic acid (HA) to prepare GSH-consuming nanovaccine HA@PC-OVA via Schiff base reaction. The GSH-consuming agent consumes GSH in dendritic cells, activates dendritic cell maturation, and enhances their antigen uptake and presentation capabilities.
The prepared HA@PC-OVA nanovaccine has uniform and stable particle size, low cytotoxicity, and can significantly promote the maturation of DC cells, activate anti-tumor immune responses, reshape the immune-activated tumor microenvironment, and enhance anti-tumor efficacy.
Smart Images
Figure CN117695386B_ABST